What is the primary use of Rufinamide?

Rufinamide is primarily used as an adjunctive treatment for Lennox-Gastaut syndrome, which is a severe form of epilepsy characterized by multiple types of seizures and developmental delays. It functions by stabilizing neuronal membranes and inhibiting sodium channels, thereby reducing seizure frequency in patients who are not adequately controlled with other medications. This specific use for Lennox-Gastaut syndrome is supported by clinical trials demonstrating its effectiveness in decreasing the number of seizures experienced by patients with this condition.

The other options do not align with Rufinamide's therapeutic indications. It is not indicated for treating insomnia or anxiety disorders, nor is it classified as an antibiotic. Thus, the focus on its adjunctive role in Lennox-Gastaut syndrome establishes its primary purpose within the context of managing epilepsy.